Lisanti Capital Growth LLC Acquires 31,285 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Lisanti Capital Growth LLC grew its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 85.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 67,900 shares of the company's stock after purchasing an additional 31,285 shares during the quarter. Lisanti Capital Growth LLC owned approximately 0.25% of GeneDx worth $5,219,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in WGS. MCF Advisors LLC grew its holdings in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after purchasing an additional 182 shares during the period. Global Retirement Partners LLC purchased a new position in shares of GeneDx during the 4th quarter valued at $28,000. Evolution Wealth Advisors LLC bought a new position in shares of GeneDx during the 4th quarter worth $202,000. Victory Capital Management Inc. purchased a new stake in GeneDx in the 4th quarter worth about $209,000. Finally, Ieq Capital LLC bought a new stake in GeneDx in the 4th quarter valued at about $220,000. 61.72% of the stock is currently owned by institutional investors.

GeneDx Price Performance

NASDAQ:WGS traded down $2.49 during mid-day trading on Tuesday, hitting $87.17. 1,014,752 shares of the stock traded hands, compared to its average volume of 607,372. The business's 50-day moving average price is $83.51 and its 200 day moving average price is $68.32. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The company has a market cap of $2.45 billion, a PE ratio of -44.47 and a beta of 1.90. GeneDx Holdings Corp. has a 12-month low of $7.72 and a 12-month high of $115.60.

Remove Ads

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66. The firm had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. The Goldman Sachs Group increased their target price on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 19th. TD Cowen raised their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, GeneDx has a consensus rating of "Moderate Buy" and a consensus target price of $72.33.

Insider Buying and Selling at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 10,501 shares of the firm's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $76.75, for a total transaction of $805,951.75. Following the sale, the chief executive officer now owns 71,146 shares in the company, valued at $5,460,455.50. This trade represents a 12.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kevin Feeley sold 3,728 shares of the company's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $76.75, for a total value of $286,124.00. Following the completion of the transaction, the chief financial officer now owns 28,200 shares of the company's stock, valued at $2,164,350. The trade was a 11.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 122,523 shares of company stock worth $10,949,480 over the last three months. 27.30% of the stock is owned by insiders.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.